Sirio Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Sirio Pharma has a total shareholder equity of CN¥3.1B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 36.1%. Its total assets and total liabilities are CN¥5.1B and CN¥2.1B respectively. Sirio Pharma's EBIT is CN¥428.4M making its interest coverage ratio 5.6. It has cash and short-term investments of CN¥603.7M.
Key information
36.1%
Debt to equity ratio
CN¥1.10b
Debt
Interest coverage ratio | 5.6x |
Cash | CN¥603.71m |
Equity | CN¥3.06b |
Total liabilities | CN¥2.07b |
Total assets | CN¥5.13b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 300791's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥611.1M).
Long Term Liabilities: 300791's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥1.5B).
Debt to Equity History and Analysis
Debt Level: 300791's net debt to equity ratio (16.4%) is considered satisfactory.
Reducing Debt: 300791's debt to equity ratio has increased from 34.7% to 36.1% over the past 5 years.
Debt Coverage: 300791's debt is well covered by operating cash flow (25%).
Interest Coverage: 300791's interest payments on its debt are well covered by EBIT (5.6x coverage).